207 related articles for article (PubMed ID: 30251745)
41. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Yabana T
Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
[TBL] [Abstract][Full Text] [Related]
42. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
[TBL] [Abstract][Full Text] [Related]
43. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
Schulze M; Stotz N; Rassweiler J
J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
[TBL] [Abstract][Full Text] [Related]
44. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
45. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
46. Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
Vanneste M; van der Heij B; Christiaansen CE; Berendsen CL; Driessen EJM; Bruins HM
World J Urol; 2023 Aug; 41(8):2173-2178. PubMed ID: 37328699
[TBL] [Abstract][Full Text] [Related]
47. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.
Klän R; Loy V; Huland H
J Urol; 1991 Aug; 146(2):316-8. PubMed ID: 1856924
[TBL] [Abstract][Full Text] [Related]
48. The evaluation of the risk factors for non-muscle invasive bladder cancer (NMIBC) recurrence after transurethral resection (TURBt) in Chinese population.
Liu S; Hou J; Zhang H; Wu Y; Hu M; Zhang L; Xu J; Na R; Jiang H; Ding Q
PLoS One; 2015; 10(4):e0123617. PubMed ID: 25849552
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder.
Gakis G; Todenhöfer T; Braun M; Fend F; Stenzl A; Perner S
Scand J Urol; 2015; 49(5):382-7. PubMed ID: 25921278
[TBL] [Abstract][Full Text] [Related]
50. Impact of a second transurethral resection on the staging of T1 bladder cancer.
Dalbagni G; Herr HW; Reuter VE
Urology; 2002 Nov; 60(5):822-4; discussion 824-5. PubMed ID: 12429307
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study.
Elsawy AA; Harraz AM; Ghobrial FK; Abdullatef M; Ali-El-Dein B
Urol Oncol; 2020 Dec; 38(12):935.e1-935.e8. PubMed ID: 32654947
[TBL] [Abstract][Full Text] [Related]
52. Positive urine cytology and carcinoma in situ prior to second transurethral resection of the bladder correlate with positive second resection histology and the need for subsequent cystectomy.
Lodde M; Mayr R; Martini T; Comploj E; Palermo S; Trenti E; Hanspeter E; Fritsche HM; Mian C; Pycha A
World J Urol; 2012 Dec; 30(6):841-6. PubMed ID: 23143733
[TBL] [Abstract][Full Text] [Related]
53. Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.
Zapała P; Dybowski B; Poletajew S; Białek Ł; Niewczas A; Radziszewski P
World J Surg Oncol; 2018 Jan; 16(1):6. PubMed ID: 29334958
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
55. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection.
Wasco MJ; Daignault S; Zhang Y; Kunju LP; Kinnaman M; Braun T; Lee CT; Shah RB
Urology; 2007 Jul; 70(1):69-74. PubMed ID: 17656211
[TBL] [Abstract][Full Text] [Related]
56. [T1 high-grade bladder cancer - value of second operation with prognostuic parameters of first operation: analysis of 167 cases].
Lazica DA; Böttcher S; Degener S; von Rundstedt FC; Brandt AS; Roth S; Störkel S; Mathers MJ
Aktuelle Urol; 2013 Mar; 44(2):124-8. PubMed ID: 23580383
[TBL] [Abstract][Full Text] [Related]
57. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
Cumberbatch MGK; Foerster B; Catto JWF; Kamat AM; Kassouf W; Jubber I; Shariat SF; Sylvester RJ; Gontero P
Eur Urol; 2018 Jun; 73(6):925-933. PubMed ID: 29523366
[TBL] [Abstract][Full Text] [Related]
58. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy.
Ark JT; Keegan KA; Barocas DA; Morgan TM; Resnick MJ; You C; Cookson MS; Penson DF; Davis R; Clark PE; Smith JA; Chang SS
BJU Int; 2014 Jun; 113(6):894-9. PubMed ID: 24053444
[TBL] [Abstract][Full Text] [Related]
59. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens.
Cheng L; Neumann RM; Weaver AL; Cheville JC; Leibovich BC; Ramnani DM; Scherer BG; Nehra A; Zincke H; Bostwick DG
Am J Clin Pathol; 2000 Feb; 113(2):275-9. PubMed ID: 10664630
[TBL] [Abstract][Full Text] [Related]
60. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
